Please use this identifier to cite or link to this item: http://sgc.anlis.gov.ar/handle/123456789/879
Title: Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial
Authors: Villar, Juan Carlos 
Herrera, Víctor Mauricio 
Pérez Carreño, Juan Guillermo 
Váquiro Herrera, Eliana 
Castellanos Domínguez, Yeny Zulay 
Vásquez, Skarlet Marcell 
Cucunubá, Zulma Milena 
Prado, Nilda Graciela 
Hernández, Yolanda 
Keywords: Enfermedad de Chagas;Nifurtimox;Benznidazole;Ensayos Clínicos Controlados Aleatorios
Issue Date: 15-Jul-2019
Journal: Trials 
Abstract: 
Either benznidazole (BZN) or nifurtimox (NFX) is recommended as equivalent to treat Trypanosoma cruzi infection. Nonetheless, supportive data from randomised trials is limited to individuals treated with BZN in southern cone countries of Latin America.
Description: 
Fil: Hernández Yolanda. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología Dr. Mario Fatala Chaben. Departamento de Clínica, Patología y Tratamiento; Argentina.
URI: http://sgc.anlis.gob.ar/handle/123456789/879
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631895/
DOI: 10.1186/s13063-019-3423-3
Rights: openAccess
Creative Commons Attribution 4.0 International License
Appears in Collections:Publicaciones INP

Files in This Item:
File Description SizeFormat
13063_2019_Article_3423.pdf1.31 MBAdobe PDFThumbnail
View/Open
Show full item record

Page view(s)

14
checked on Jul 4, 2020

Download(s)

8
checked on Jul 4, 2020

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons